Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC. MRI-based assessment may eliminate the need for transurethral resection of bladder tumor ...
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...
More than 250,000 people undergo a transurethral procedure each year in the U.S., and up to 10% of those people will experience a postoperative infection. But researchers have discovered an indicator ...
UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
Department of Urology, All India Institute of Medical Sciences (AIIMS) Jammu, has commenced advanced endourological services, ...
Use of multiparametric MRI for the initial staging of suspected MIBC shortened the time to correct treatment compared with TURBT. Incorporating multiparametric MRI (mpMRI) into the initial staging of ...
PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
or on the link below. Non–muscle-invasive bladder cancer (NMIBC) comprises 75% of newly diagnosed bladder cancer and poses significant clinical challenges because of high recurrence and progression ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback